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Matrix metalloproteinase-7 (MMP-7) is a secreted zinc- and calcium-dependent
endopeptidase that degrades a broad range of extracellular matrix substrates and
additional substrates. MMP-7 playsa crucial role in a diverse array of cellular processes
and appears to be a key regulator of fibrosis in several diseases, including pulmonary
fibrosis, liver fibrosis, and cystic fibrosis. In particular, the relationship between MMP-7
and kidney fibrosis has attracted significant attention in recent years. Growing evidence
indicates that MMP-7 plays an important role in the pathogenesis of kidney fibrosis.
Here, we summarize the recent progress in the understanding of the role of MMP-7 in
kidney fibrosis. In particular, we discuss howMMP-7 contributes to kidney fibrotic lesions
via the following three pathways: epithelial-mesenchymal transition (EMT), transforming
growth factor-beta (TGF-β) signaling, and extracellular matrix (ECM) deposition. Further
dissection of the crosstalk among and regulation of these pathways will help clinicians
and researchers develop effective therapeutic approaches for treating chronic kidney
disease.
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INTRODUCTION
The prevalence of chronic kidney disease (CKD) in the United States is decreasing, but its incidence
worldwide continues to increase (Fried and Palevsky, 2016; Zhang et al., 2016). Renal fibrosis,
the common final outcome of a wide variety of progressive CKDs, is a complicated process
characterized by increased fibroblast proliferation and extracellular matrix (ECM) accumulation,
which lead to renal tubule fibrosis, glomerular sclerosis, renal artery stenosis, and chronic
inflammatory cell infiltration (Liu, 2011). It is believed that themechanism underlying renal fibrosis
development is related to ECM accumulation caused by epithelial-mesenchymal transition (EMT),
transforming growth factor-beta (TGF-β) signaling, chronic hypoxia, and oxidative stress (Liu,
2011). Unfortunately, there is no effective cure for renal fibrosis, and its progression to end-stage
renal disease (ESRD) necessitates dialysis or kidney transplantation (Boor et al., 2010; Liu, 2011).
Metalloproteinase-7 (MMP-7) is a secreted zinc- and calcium-dependent endopeptidase that
degrades a broad range of ECM substrates (Brabletz et al., 1999; Tan and Liu, 2012). MMP-7 is also
known to cleave non-ECM proteins, such as E-cadherin and Fas ligand (FasL), and thus plays an
important role in the regulation of diverse biological processes, such as EMT and cell apoptosis
(Mitsiades et al., 2001; McGuire et al., 2003; Ii et al., 2006). MMP-7 is a downstream target gene of
Wnt/β-catenin signaling and is involved in renal fibrosis via β-catenin signaling (Tan et al., 2014).
Recent evidence suggests that MMP-7 is not only a biomarker for renal fibrosis but also a major
pathogenic mediator in fibrotic lesion progression (Zhou et al., 2016). Mice with genetically ablated
MMP-7 are largely protected against the development of renal fibrotic lesions after unilateral
Ke et al. Matrix Metalloproteinases-7 and Kidney Fibrosis
ureteral obstruction (UUO) and display much less collagen 1 and
fibronectin accumulation and deposition in renal parenchyma,
as well as reduced myofibroblast activation (Zhou et al., 2016).
Furthermore, MMP-7 promotes renal fibrosis by inducing E-
cadherin proteolytic degradation, ECM accumulation, and TGF-
βsignaling activation (He et al., 2012; Oelusarz et al., 2013; Xiao
et al., 2016). Pharmacological blockade of MMP-7 expression
effectively attenuates renal injury and fibrosis (Xiao et al., 2016).
Therefore, in this review, we aim to summarize recent findings
regarding the role of MMP-7 in the pathogenesis of kidney
fibrosis to facilitate the development of effective therapies for
CKD.
BIOLOGICAL CHARACTERISTICS OF
MMP-7
Matrix metalloproteinases (MMPs) are zinc-containing
endopeptidases with a broad range of substrate specificities. They
are secreted by keratinocytes and dermal fibroblasts in response
to multiple stimuli, such as oxidative stress, UV radiation, and
cytokines (Kim et al., 2011; Hwang et al., 2012; Ham et al., 2014).
At least 28 different types of MMPs that play important roles in
various pathophysiological processes, including aging, wound
healing, skeletal growth, and remodeling, arthritis, inflammation,
angiogenesis, and cancer (Jung et al., 2010; Sbardella et al., 2012),
have been identified.
MMP-7, also known as matrilysin, matrilysin-1, and pump-
punctuated metalloproteinase, is the smallest member of the
MMP family (Muller et al., 1988; Woessner and Taplin, 1988;
Quantin et al., 1989; Miyazaki et al., 1990; Abramson et al., 1995).
MMP-7 is structurally different from the other members of the
family because it lacks a C-terminal hemopexin domain (Gaire
et al., 1994). MMP-7 is expressed at very low levels in adults and
in only a few tissues but is upregulated in a variety of disease
states, including cancer and idiopathic pulmonary fibrosis (Zuo
et al., 2002; Huang et al., 2005; Ramankulov et al., 2008).
Increasing evidence suggests that MMP-7 plays an active
role in renal pathology. MMP-7 contributes to renal tubular
injury and tubulointerstitial fibrosis progression via Wnt 4
(Surendran et al., 2004). MMP-7 expression is not detected
in healthy human renal tubular epithelium (Surendran et al.,
2004). However, MMP-7 expression is upregulated in autosomal
dominant polycystic kidney disease (Riera et al., 2006), renal
biopsy samples from hydronephrotic patients with progressive
disease requiring hemodialysis (Henger et al., 2004) and canine
X-linked Alport syndrome (Rao et al., 2005). In addition,
MMP-7 has been implicated in renal carcinoma development
and progression (Patraki and Cardillo, 2007; Sarkissian et al.,
2008). Moreover, MMP-7 is part of a group of genes that were
significantly upregulated in very old kidneys exhibiting a higher
rate of histopathological changes, including glomerulosclerosis,
interstitial fibrosis and tubular atrophy (Melk et al., 2005).
Consequently, significant effort has been expended to understand
the molecular and cellular mechanisms by which MMP-7
contributes to kidney fibrosis. Below, we will discuss three main
pathways that were recently identified as linking MMP-7 with
kidney fibrosis.
MMP-7 and EMT
During EMT, renal epithelial cells are transformed into
mesenchymal cells. These mesenchymal cells ameliorate tissue
damage, causing the accumulation of ECM and the production
of myofibroblasts, which are key effectors in ECM synthesis and
deposition. EMT is characterized by reduced cell-cell contact,
reduced expression of epithelial markers such as E-cadherin, and
increased expression of mesenchymal markers such as α-SMA,
type I collagen, and fibronectin (Son and Moon, 2010). Although
many studies have shown that EMT in the kidney may lead to
renal fibrosis, the relationship between EMT and renal fibrosis
remains controversial (Menon and Ross, 2016).
MMP-7 mediates tubular epithelial-interstitial fibroblast
communication through Wnt/β-catenin signaling (Zhou et al.,
2013, Figure 1), an evolutionarily conserved pathway that
regulates cell fate, organ development, and tissue homeostasis,
as well as injury and repair. Wnt/β-catenin signaling is
relatively silent in the normal adult kidney but is activated
after renal injury in a wide variety of animal models and
human kidney disorders (Clevers and Nusse, 2012). Canonical
Wnt signaling activation leads to β-catenin stabilization and
nuclear translocation, followed by binding of β-cateninto T
cell factor (TCF)/lymphoidenhancer–binding factor to stimulate
the transcription of Wnt target genes, a common pathological
occurrence in a wide variety of CKDs (Nelson et al., 2011).
Tubular activation of β-catenin after injury leads to EMT
and upregulates tubular expression and secretion of MMP-
7 (Liu, 2010; He et al., 2012). As a result, secreted MMP-
7 induces the expression of FasL, a key player in the
extrinsic, receptor-mediated apoptosis pathway (Villa-Morales
and Fernandez-Piqueras, 2012), in interstitial fibroblasts and
potentiates apoptosis of these cells (Zhou et al., 2013). Loss
of tubular β-catenin results in enhanced interstitial fibroblast
survival due to decreased MMP-7 expression (Zhou et al.,
2013).
MMP-7 induces E-cadherin proteolytic degradation and β-
catenin signaling activation independent of Wnt to promote
EMT (McGuire et al., 2003; Zhou et al., 2016). E-cadherin is an
epithelial cell adhesion receptor essential for the maintenance of
tubular epithelial integrity. E-cadherin destruction is the initial
step during EMT and disrupts tubular epithelial cell integrity
(Liu, 2004). Shibata et al. (2009) found that MMP-7 reduces
E-cadherin levels and promotes EMT in diseased kidneys,
contributing to tubular epithelial injury (Zhou et al., 2013).
One consequence of MMP-7-mediated E-cadherin degradation
is β-catenin liberation independent of Wnt (Zhou et al., 2016).
The liberated β-catenin then translocates into the nucleus as
a transcription regulator and drives the expression of target
genes, including MMP-7(He et al., 2010; Tan and Liu, 2012).
An MMP-7-knockout mouse model showed that MMP-7 is an
important pathogenic mediator that triggers the activation of
β-catenin signaling and promotes renal fibrosis (Zhou et al.,
2016).
MMP-7 also degrades collagen type IV and laminin to induce
EMT (Tan and Liu, 2012, Figure 1). MMP-7 cleaves not only
elastin but also many other ECM substrates, such as collagen
type IV and laminin (Sbardella et al., 2012), which are the
major components of the tubular basement membrane (TBM).
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FIGURE 1 | MMP-7, which is expressed upon β-catenin activation, mediates EMT through the following 3 pathways. (A) Inducing FasL expression in
interstitial fibroblasts and potentiating their apoptosis. (B) Inducing tubular epithelial integrity destruction by regulating E-cadherin degradation. (C) Inducing TBM
destruction by degrading collagen type IV and laminin.
Increased MMP-7 aggravates TBM damage, which facilitates
tubular EMT in fibrotic kidneys (Tan and Liu, 2012).
Advanced CKD is characterized by chronic hypoxia in the
renal interstitium (Mimura and Nangaku, 2010). Hypoxia can
lead to tubular EMT or apoptosis, activate resident fibroblasts
and impair peritubular capillaries, creating a cycle of chronic
hypoxia and resulting in renal fibrosis (Liu, 2011). MMP-7 is a
major MMP activator in conditioned medium of hypoxic bladder
smooth muscle cells (BSMCs) and is also transcriptionally
induced at 6 h of hypoxia in an Erkl/2-dependent manner (Sabha
et al., 2006). In addition, MMP-7 is upregulated in macrophages
at sites of inflammation, such as wounds and tumors, in response
to hypoxia (Crowther et al., 2001). The increase in the ratio
of active (18 kDa) to inactive (28 kDa) MMP-7 coincides with
the peak period of hypoxia-induced Erkl/2 activation. Moreover,
hypoxia activates β-catenin in human macrophages by inducing
MMP-7mRNA expression (Deguchi et al., 2009).
MMP-7 and TGF-β Signaling
TGF-β is a pleiotropic cytokine that plays an important role in
cell proliferation and differentiation and induces the synthesis of
ECM components. TGF-β is also a major cytokine/growth factor
involved in renal fibrosis (Meng et al., 2012). Smad proteins are
highly conserved transcription factors that mediate numerous
effects of the TGF-β superfamily (Massague, 2012). TGF-β1
stimulates renal tubular EMT, which is a crucial process in
tubulointerstitial fibrosis development (Carew et al., 2012).
Recent studies have revealed the existence of a close
relationship between MMP-7 and TGF-β signaling (Figure 2). Li
et al. (2017) observed that the expression of TGF-β1 and MMP-7
are upregulated in STZ-induced diabetic nephropathy rats but
markedly decreased in diabetic nephropathy rats treated with
sodium hydrosulfide (Li et al., 2017), which suggests regulation
between TGF-β and MMP-7. MMP-7 is also closely related to
TGF-β/Smad4 signaling (Xiao et al., 2016). Sirtuin 1 (SIRT1), a
nicotinamide adenine dinucleotide (NAD+)-dependent class III
deacetylase that can deacetylate both histone and non-histone
proteins, has been shown to participate in numerous cellular
processes by deacetylating specific substrates. In particular,
SIRT1 has shown reno protective effects in several models
of acute kidney injury (Fan et al., 2013) and chronic kidney
diseases (Hasegawa et al., 2013). SIRT1 inhibits MMP-7 protein
expression by deacetylating Smad4, a transcription factor for
MMP-7 expression, whereas SIRT1 inhibition induces MMP-7
upregulation (Xiao et al., 2016). Simic et al. (2013) found that
TGF-β regulates MMP-7 expression, whereas SIRT1 deacetylates
Smad4 and represses MMP-7 activity. SIRT1 regulates MMP-
7 expression and enzyme activity via Smad4 deacetylation.
Moreover, Thiery et al. (2009) found that TGF-β-induced β-
catenin is required for the synthesis of a-SMA, a marker
of EMT, in renal proximal tubular cells. Moreover, β-catenin
promotes EMT further by upregulating MMP-7(Zhou et al.,
2013). However, TGF-β suppresses the expression of several
MMPs by binding of the c-fos proto-oncogene product Fos
protein to TGF-β inhibitory elements in the promoter regions of
MMP genes (Kerr et al., 1990). McLennan et al. (2007) found that
MMP-7 levels are reduced in streptozotocin-induced diabetic
nephropathy rats via TGF-β-dependent mechanisms; thus, TGF-
β induction may contribute to reductions in MMP-7 expression
and ECM accumulation in diabetic nephropathy.
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FIGURE 2 | Two molecular pathways may be involved in the mechanisms by which TGF-β regulates MMP-7 expression. (A) TGF-β can induce β-catenin
expression directly. (B) Smad4 deacetylation can suppress MMP-7 expression by promoting the binding of the Fos protein complex to the TGF-β inhibitory element,
indicating that normal Smad4 can induce MMP-7 expression via TGF-β signaling.
Interestingly, an MMP-7/syndecan-1/TGF-β1 autocrine
loop leading to TGF-β1 production has been identified in
hepatocellular carcinoma (Zeng et al., 2016). Further studies
are needed to investigate whether a similar loop exists in renal
fibrosis.
MMP-7 and the ECM
Aberrant thickening of the glomerular basement membrane
(GBM) and TBM, as well as excessive accumulation of mesangial
matrices in renal fibrosis, is the result of an imbalance between
the synthesis and degradation of ECM components. ECM
deposition in renal structures, such as the glomerular capillary
wall, arterioles, mesangium, and tubule-interstitial space, will
ultimatelycause renal fibrosis (Duffield, 2014). The major ECM
component perturbations that occur in the GBM include
increases in collagen type IV (α 3 and α 4 chains), laminin
and fibronectin expression (Hu et al., 2015). The molecules
involved in increased ECM deposition in kidney fibrosis have
been investigated extensively, especially MMP-7 (Xu et al., 2014).
MMP-7 can alter the micro-architecture of the glomerular
apparatus and degrades collagen type IV, small proteoglycans,
fibronectin, laminin, and entactin, all of which are components
of the glomerular ECM (Tan and Liu, 2012). In addition, MMP-
7 enhances the actions of growth factors. For instance, aberrant
renal growth is preceded by a marked increase in the expression
of intra-renal insulin-like growth factor (IGF)-I protein, which
is trafficked into the kidney as a result of changes in IGF-
binding protein (IGFBP) expression within renal tissues rather
than enhancements in local IGF-I production (Flyvbjerg, 2000).
Specifically, induction of IGFBP-1, 3, and 5 expression has
been demonstrated in early renal hypertrophy in streptozotocin-
treated diabetic rats (Park et al., 1998). Consequently, MMP-7
overproduction in kidney parenchyma may result in enhanced
degradation of IGFBPs and the release of free bioactive IGFs,
leading to expansion of the mesangium. MMP-7 has been
shown to proteolytically degrade IGFBP-3 and IGFBP-5, and
IGFBP cleavage by MMP-7 can liberate IGF-II (Miyamoto et al.,
2004; Hemers et al., 2005; McCaig et al., 2006). Moreover,
increased Col1a2 and Col3a1 expression are correlated with
fibrotic changes in the kidney (Fragiadaki et al., 2011). A recent
study reported that early MMP-7 upregulation increases Col1a2
and Col3a1 transcription primarily via PIK3, p38, ERK, Src, and
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PKA signaling, leading to subsequent collagen deposition in the
kidney (Oelusarz et al., 2013). Taken together, these data suggest
thatMMP-7 activity may contribute, either directly or indirectly,
to GBM thickening and mesangial expansion, which precede the
onset of kidney fibrotic lesions.
CONCLUSION AND PERSPECTIVE
MMP-7 plays an active role in renal fibrosis mainly through
the following three pathways: EMT, TGF-β signaling and
ECM deposition. These pathways interact with one another
and contribute to the development of kidney fibrotic lesions.
Several studies have suggested that MMP-7 is a potential
target in renal fibrosis treatment. Resveratrol (RSV; trans-3,5,4′-
trihydroxystilbene), a stilbene polyphenol from grapes, wine,
mulberries, and peanuts, has been reported to have various
pharmacological effects, including cardio protective effects in
coronary heart disease, anti-inflammatory effects, and chemo
preventive effects in cancer (Bhat et al., 2001; Aggarwal et al.,
2004). RSV attenuates renal injury and fibrosis by inhibiting
EMT, which is induced by upregulation of MMP-7 expression
(Xiao et al., 2016). Moreover, compared with levels in normal
subjects, patients with various kidney disorders have markedly
elevated urinary MMP-7 levels, which are closely correlated
with renal fibrosis scores in these patients (Zhou et al., 2016).
In addition, among people with type 2 diabetes, urine, and
serum MMP-7 levels are strongly associated with diabetic
complications, namely, renal disease (Afkarian et al., 2015).
Collectively, these results suggest that MMP-7 may not only be
a potential target but also a noninvasive biomarker of kidney
fibrosis.
However, a recent study investigating the potential correlation
of urinary/serum MMPS/tissue inhibitors of metalloproteases
(TIMPS) with subclinical progressive interstitial fibrosis and
tubular atrophy (IF/TA) within the first 6 months post-renal
transplant indicated that urinary MMP-7 was higher during
subclinical tubulitis (p < 0.04) and that serum MMP-7 was
barely correlated with subclinical IF/TA (Hirt-Minkowski et al.,
2014). Thus, to deepen the understanding of the role of MMP-
7 in the clinical treatment of kidney fibrosis, additional studies
are needed to elucidate the molecular mechanisms by which
MMP-7 contributes to the development of kidney fibrosis. These
investigations will help researchers develop potential diagnostic
biomarkers of and therapeutic targets for kidney fibrosis.
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